Nothing Special   »   [go: up one dir, main page]

DK3404041T3 - Fremgangsmåde til behandling af osteoporose - Google Patents

Fremgangsmåde til behandling af osteoporose Download PDF

Info

Publication number
DK3404041T3
DK3404041T3 DK18182009.3T DK18182009T DK3404041T3 DK 3404041 T3 DK3404041 T3 DK 3404041T3 DK 18182009 T DK18182009 T DK 18182009T DK 3404041 T3 DK3404041 T3 DK 3404041T3
Authority
DK
Denmark
Prior art keywords
treating osteoporosis
osteoporosis
treating
Prior art date
Application number
DK18182009.3T
Other languages
English (en)
Inventor
Martin Javier San
Scott Wasserman
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of DK3404041T3 publication Critical patent/DK3404041T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Removal Of Specific Substances (AREA)
  • Steroid Compounds (AREA)
DK18182009.3T 2011-04-19 2012-04-18 Fremgangsmåde til behandling af osteoporose DK3404041T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161477065P 2011-04-19 2011-04-19
EP12717002.5A EP2699261B1 (en) 2011-04-19 2012-04-18 Method for treating osteoporosis

Publications (1)

Publication Number Publication Date
DK3404041T3 true DK3404041T3 (da) 2020-08-24

Family

ID=46000402

Family Applications (2)

Application Number Title Priority Date Filing Date
DK18182009.3T DK3404041T3 (da) 2011-04-19 2012-04-18 Fremgangsmåde til behandling af osteoporose
DK12717002.5T DK2699261T3 (da) 2011-04-19 2012-04-18 Fremgangsmåde til behandling af osteoporose

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK12717002.5T DK2699261T3 (da) 2011-04-19 2012-04-18 Fremgangsmåde til behandling af osteoporose

Country Status (15)

Country Link
US (1) US20140127192A1 (da)
EP (2) EP2699261B1 (da)
AU (1) AU2012245495A1 (da)
CA (1) CA2833289A1 (da)
CY (2) CY1121527T1 (da)
DK (2) DK3404041T3 (da)
ES (2) ES2823240T3 (da)
HR (2) HRP20181649T1 (da)
HU (1) HUE052094T2 (da)
LT (2) LT3404041T (da)
PL (2) PL3404041T3 (da)
PT (2) PT2699261T (da)
RS (2) RS60835B1 (da)
SI (2) SI3404041T1 (da)
WO (1) WO2012145417A1 (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220162801A (ko) 2008-04-11 2022-12-08 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
WO2012073992A1 (ja) 2010-11-30 2012-06-07 中外製薬株式会社 複数分子の抗原に繰り返し結合する抗原結合分子
EP3285792B1 (en) * 2015-04-20 2020-11-04 The Board of Regents of The University of Texas System Clec11a is a bone growth agent
JP2020502218A (ja) 2016-12-21 2020-01-23 メレオ バイオファーマ 3 リミテッド 骨形成不全症の処置における抗スクレロスチン抗体の使用
JP7191833B2 (ja) 2017-01-30 2022-12-19 中外製薬株式会社 抗スクレロスチン抗体およびその使用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
US6316408B1 (en) * 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
US6673901B2 (en) 1997-06-12 2004-01-06 Research Corporation Technologies, Inc. Artificial antibody polypeptides
NZ552959A (en) 1998-11-27 2008-06-30 Darwin Discovery Ltd Compositions and methods for increasing bone mineralization
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
ES2586401T3 (es) 2003-06-16 2016-10-14 Ucb Pharma S.A. Anticuerpos específicos para la esclerostina y métodos para aumentar la mineralización ósea
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
US8003108B2 (en) * 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
AU2008209713B2 (en) 2007-02-02 2012-01-19 Novartis Ag Modulators of sclerostin binding partners for treating bone-related disorders
JP2010524846A (ja) 2007-03-20 2010-07-22 イーライ リリー アンド カンパニー 抗スクレロスチン抗体
CL2008002775A1 (es) * 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
TWI489993B (zh) 2007-10-12 2015-07-01 Novartis Ag 骨硬化素(sclerostin)抗體組合物及使用方法
WO2009056634A2 (en) 2007-11-02 2009-05-07 Novartis Ag Molecules and methods for modulating low-density-lipoprotein receptor-related protein 6 (lrp6)
WO2010100200A2 (en) 2009-03-05 2010-09-10 Novartis Ag Lyophilised antibody formulation
WO2010100179A2 (en) 2009-03-05 2010-09-10 Novartis Ag Self-forming gel system for sustained drug delivery
WO2010115932A1 (en) 2009-04-08 2010-10-14 Novartis Ag Combination for the treatment of bone loss
WO2010130830A2 (en) 2009-05-15 2010-11-18 Ablynx N.V. Amino acid sequences directed against sclerostin and polypeptides comprising the same for the treatment of bone diseases and disorders

Also Published As

Publication number Publication date
PT3404041T (pt) 2020-07-30
PL3404041T3 (pl) 2020-12-14
ES2823240T3 (es) 2021-05-06
SI2699261T1 (sl) 2018-11-30
RS57877B1 (sr) 2018-12-31
WO2012145417A1 (en) 2012-10-26
EP2699261A1 (en) 2014-02-26
US20140127192A1 (en) 2014-05-08
RS60835B1 (sr) 2020-10-30
SI3404041T1 (sl) 2020-11-30
LT3404041T (lt) 2020-08-25
CA2833289A1 (en) 2012-10-26
HRP20181649T1 (hr) 2018-12-14
DK2699261T3 (da) 2018-09-17
EP2699261B1 (en) 2018-07-11
EP3404041A1 (en) 2018-11-21
ES2685479T3 (es) 2018-10-09
CY1121527T1 (el) 2020-05-29
HUE052094T2 (hu) 2021-04-28
PT2699261T (pt) 2018-10-22
EP3404041B1 (en) 2020-07-22
AU2012245495A1 (en) 2013-11-07
HRP20201366T1 (hr) 2020-11-27
LT2699261T (lt) 2018-11-12
PL2699261T3 (pl) 2018-12-31
CY1123513T1 (el) 2022-03-24

Similar Documents

Publication Publication Date Title
DK2709613T4 (da) Fremgangsmåder til behandling af hcv
DK3543333T3 (da) Fremgangsmåde til screening af alfa-amylaser
HK1201040A1 (en) Method for treating osteoporosis
DK2857019T3 (da) Fremgangsmåde til behandling af multipel sklerose
DK2766392T3 (da) Fremgangsmåde til oprensning af antistoffer
DK2683384T3 (da) Fremgangsmåder til behandling af cancer under anvendelse af 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidin-2,6-dion
DK2758172T3 (da) System til udførelse af reaktioner
BR112014007958A2 (pt) método
BR112014001765A2 (pt) método
DK2732131T3 (da) Positioneringsfremgangsmåde
BR112014001237A2 (pt) método
DK3322183T3 (da) Fremgangsmåde til intraforudsigelse af video
BR112014009795A2 (pt) método
ZA201208219B (en) Method for treating wasterwater
BR112013022820A2 (pt) método de tratamento
DK2536422T3 (da) Fremgangsmåder til behandling af diabetiske fodsår
HRP20181649T1 (hr) Metoda liječenja osteoporoze
DK2489276T3 (da) Fremgangsmåde til udvinding af olie
DK2701707T3 (da) Fremgangsmåde til behandling af dyskinesi
DK3081097T3 (da) Sammensætning til behandling af infertilitet
DK2476534T3 (da) Fremgangsmåde til formning
DK2900606T3 (da) Indretning til behandling af ballastvand
DK3202769T3 (da) Fremgangsmåde til oprensning af phosphaplatinforbindelser
DK3536410T3 (da) Fremgangsmåde til behandling af affaldsgenstande
DK2481821T3 (da) Fremgangsmåde til behandling af læder